Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine : two randomized, parallel-controlled, phase 2 studies
BACKGROUND: Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.
RESEARCH DESIGN AND METHODS: Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirates. Study-2 participating individuals were randomized (1:1:1) to receive 20 μg ReCOV (pilot batch, ReCOV HA), 20 μg ReCOV (commercial batch, ReCOV TC), or 30 μg BNT162b2 (COMIRNATY®) in the Philippines. The primary immunogenicity objectives was to compare the geometric mean titer (GMT) and seroconversion rate (SCR) of neutralizing antibodies induced by one ReCOV booster dose with those of inactivated vaccine and BNT162b2, respectively, at 14 days post-booster.
RESULTS: Heterologous ReCOV booster doses were safe and induced comparable immune responses to inactivated vaccines and BNT162b2 against Omicron variants and the prototype. They showed significant advantages in cross-neutralization against multiple SARS-CoV-2 variants, surpassing inactivated vaccines and BNT162b2, with good immune persistence.
CONCLUSIONS: Heterologous ReCOV boosting was safe and effective, showing promise in combating COVID-19. The study highlights ReCOV's potential for enhanced protection, supported by strong cross-neutralization and immune persistence.
CLINICAL TRIAL REGISTRATION: Study-1, www.clinicaltrials.gov, identifier is NCT05323435; Study-2, www.clinicaltrials.gov, identifier is NCT05084989.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert review of vaccines - 23(2024), 1 vom: 03. Jan., Seite 419-431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Balgos, Abundio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.04.2024 Date Revised 04.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT05084989, NCT05323435 Citation Status MEDLINE |
|---|
| doi: |
10.1080/14760584.2024.2334423 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370192508 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370192508 | ||
| 003 | DE-627 | ||
| 005 | 20240404235159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14760584.2024.2334423 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM370192508 | ||
| 035 | |a (NLM)38529685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Balgos, Abundio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine |b two randomized, parallel-controlled, phase 2 studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05084989, NCT05323435 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials | ||
| 520 | |a RESEARCH DESIGN AND METHODS: Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirates. Study-2 participating individuals were randomized (1:1:1) to receive 20 μg ReCOV (pilot batch, ReCOV HA), 20 μg ReCOV (commercial batch, ReCOV TC), or 30 μg BNT162b2 (COMIRNATY®) in the Philippines. The primary immunogenicity objectives was to compare the geometric mean titer (GMT) and seroconversion rate (SCR) of neutralizing antibodies induced by one ReCOV booster dose with those of inactivated vaccine and BNT162b2, respectively, at 14 days post-booster | ||
| 520 | |a RESULTS: Heterologous ReCOV booster doses were safe and induced comparable immune responses to inactivated vaccines and BNT162b2 against Omicron variants and the prototype. They showed significant advantages in cross-neutralization against multiple SARS-CoV-2 variants, surpassing inactivated vaccines and BNT162b2, with good immune persistence | ||
| 520 | |a CONCLUSIONS: Heterologous ReCOV boosting was safe and effective, showing promise in combating COVID-19. The study highlights ReCOV's potential for enhanced protection, supported by strong cross-neutralization and immune persistence | ||
| 520 | |a CLINICAL TRIAL REGISTRATION: Study-1, www.clinicaltrials.gov, identifier is NCT05323435; Study-2, www.clinicaltrials.gov, identifier is NCT05084989 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a heterologous booster | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a omicron variants | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Hannawi, Suad |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wen-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Abuquta, Alaa |e verfasserin |4 aut | |
| 700 | 1 | |a Safeldin, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Aala |e verfasserin |4 aut | |
| 700 | 1 | |a Alamadi, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Tirador, Louie |e verfasserin |4 aut | |
| 700 | 1 | |a Jaen, Anjuli May |e verfasserin |4 aut | |
| 700 | 1 | |a Villalobos, Ralph Elvi |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Yue, Zi-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qing-Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Ren-Du |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jia-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Wen-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jian-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Kun-Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing-Xin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of vaccines |d 2002 |g 23(2024), 1 vom: 03. Jan., Seite 419-431 |w (DE-627)NLM126545200 |x 1744-8395 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:419-431 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14760584.2024.2334423 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 03 |c 01 |h 419-431 | ||